8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
Published . Updated .
Key takeaways
- 8-K - Rapport Therapeutics filed an 8-K with the SEC on Oct 30 (a notice of a material company event).
- Exposed: RAPP
- Market reaction: RAPP −5.2% after three sessions
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Rapport Therapeutics filed an 8-K with the SEC on Oct 30 (a notice of a material company event).
Directly affected
- RAPP Rapport Therapeutics-11.9% 18d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Rapport Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and is a peer of Rapport Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson is a peer of Rapport Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+12.0% 30d
AbbVie is a peer of Rapport Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.5% 30d
Merck is a peer of Rapport Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+10.0% 30d
Abbott Laboratories is a peer of Rapport Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| RAPP | +1.16% | -10.15% | base | +0.36% | +1.68% | +3.58% | -5.22% |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | +2.59% | +0.17% |
| LLY | -9.71% | -8.92% | base | -0.37% | -0.54% | +0.07% | -3.00% |
| JNJ | -2.53% | -0.72% | base | -0.98% | -2.59% | +1.13% | -0.32% |
| ABBV | -2.71% | -2.90% | base | -2.03% | -3.03% | -0.45% | -1.91% |
| MRK | -5.94% | -5.65% | base | -0.74% | -3.26% | +0.55% | -1.48% |
| ABT | -1.26% | -3.36% | base | +3.81% | +2.97% | +9.08% | +6.88% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-10-30 AccNo: 0001193125-26-441851 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 2.03: Creation of a Direct Financial Obligation or an Obligation u…
Source: sec-edgar
The price since 30 Oct 2026: Rapport Therapeutics (RAPP) versus the S&P 500
Since the first closing price after “8-K - Rapport Therapeutics, Inc. (0002012593) (Filer),” Rapport Therapeutics (RAPP) is +2.89%.
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | -2.03% | final price |
| ABBV | the next day | -3.03% | final price |
| ABBV | two days later | -0.45% | final price |
| ABBV | three days later | -1.91% | final price |
| ABBV | three days earlier | -2.90% | final price |
| ABBV | five days earlier | -2.71% | final price |
| ABT | that day | +3.81% | final price |
| ABT | the next day | +2.97% | final price |
| ABT | two days later | +9.08% | final price |
| ABT | three days later | +6.88% | final price |
| ABT | three days earlier | -3.36% | final price |
| ABT | five days earlier | -1.26% | final price |
| JNJ | that day | -0.98% | final price |
| JNJ | the next day | -2.59% | final price |
| JNJ | two days later | +1.13% | final price |
| JNJ | three days later | -0.32% | final price |
| JNJ | three days earlier | -0.72% | final price |
| JNJ | five days earlier | -2.53% | final price |
| LLY | that day | -0.37% | final price |
| LLY | the next day | -0.54% | final price |
| LLY | two days later | +0.07% | final price |
| LLY | three days later | -3.00% | final price |
| LLY | three days earlier | -8.92% | final price |
| LLY | five days earlier | -9.71% | final price |
| MRK | that day | -0.74% | final price |
| MRK | the next day | -3.26% | final price |
| MRK | two days later | +0.55% | final price |
| MRK | three days later | -1.48% | final price |
| MRK | three days earlier | -5.65% | final price |
| MRK | five days earlier | -5.94% | final price |
| Rapport Therapeutics (RAPP) | that day | +0.36% | final price |
| Rapport Therapeutics (RAPP) | the next day | +1.68% | final price |
| Rapport Therapeutics (RAPP) | two days later | +3.58% | final price |
| Rapport Therapeutics (RAPP) | three days later | -5.22% | final price |
| Rapport Therapeutics (RAPP) | three days earlier | -10.15% | final price |
| Rapport Therapeutics (RAPP) | five days earlier | +1.16% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | two days later | +2.59% | final price |
| XLV | three days later | +0.17% | final price |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Congressional trades in the stocks in this story
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 4 days after publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 10 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 23 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 30 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 23 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 46 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 36 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 72 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Abbott Laboratories (ABT) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 23 days before publication. Filed 5 Nov 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Rapport Therapeutics (RAPP)
Companies carried with this story
- RAPP Rapport Therapeutics
In “8-K - Rapport Therapeutics, Inc. (0002012593) (Filer),” Rapport Therapeutics (RAPP) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> RAPP
How “8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)” reaches Rapport Therapeutics (RAPP)
Rapport Therapeutics (RAPP) is the company in “8-K - Rapport Therapeutics, Inc. (0002012593) (Filer),” the 30 Oct 2026 this story story.
What ties Rapport Therapeutics (RAPP) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> RAPP
Price levels for Rapport Therapeutics (RAPP)
RAPP traded between 22.08 and 31.26 across 18 sessions. The latest close on file is 25.82.
How strong the case is around Rapport Therapeutics (RAPP)
14 out of 100
“8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.